Prognostic value of day-of-injury plasma GFAP and UCH-L1 concentrations for predicting functional recovery after traumatic brain injury in patients from the US TRACK-TBI cohort: an observational cohort study

Background The prognostic value of glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1) as day-of-injury predictors of functional outcome after traumatic brain injury is not well understood. GFAP is a protein found in glial cells and UCH-L1 is found in neurons, and these biomarkers have been cleared to aid in decision making regarding whether brain CT should be performed after traumatic brain injury. We aimed to quantify their prognostic accuracy and investigate whether these biomarkers contribute novel prognostic information to existing clinical models. Methods We enrolled patients from the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) observational cohort study. TRACK-TBI includes patients 17 years and older who are evaluated for TBI at 18 US level 1 trauma centres. All patients receive head CT at evaluation, have adequate visual acuity and hearing preinjury, and are fluent in either English or Spanish. In our analysis, we included participants aged 17-90 years who had day-of-injury plasma samples for measurement of GFAP and UCH-L1 and completed 6-month assessments for outcome due to traumatic brain injury with the Glasgow Outcome Scale-Extended (GOSE-TBI). Biomarkers were analysed as continuous variables and in quintiles. This study is registered with ClinicalTrials.gov, NCT02119182. Findings We enrolled 2552 patients from Feb 26, 2014, to Aug 8, 2018. Of the 1696 participants with brain injury and data available at baseline and at 6 months who were included in the analysis, 120 (7 center dot 1%) died (GOSE-TBI=1), 235 (13 center dot 9%) had an unfavourable outcome (ie, GOSE-TBI =4), 1135 (66 center dot 9%) had incomplete recovery (ie, GOSE-TBI <8), and 561 (33 center dot 1%) recovered fully (ie, GOSE-TBI=8). The area under the curve (AUC) of GFAP for predicting death at 6 months in all patients was 0 center dot 87 (95% CI 0 center dot 83-0 center dot 91), for unfavourable outcome was 0 center dot 86 (0 center dot 83-0 center dot 89), and for incomplete recovery was 0 center dot 62 (0 center dot 59-0 center dot 64). The corresponding AUCs for UCH-L1 were 0 center dot 89 (95% CI 0 center dot 86-0 center dot 92) for predicting death, 0 center dot 86 (0 center dot 84-0 center dot 89) for unfavourable outcome, and 0 center dot 61 (0 center dot 59-0 center dot 64) for incomplete recovery at 6 months. AUCs were higher for participants with traumatic brain injury and Glasgow Coma Scale (GCS) score of 3-12 than for those with GCS score of 13-15. Among participants with GCS score of 3-12 (n=353), adding GFAP and UCH-L1 (alone or combined) to each of the three International Mission for Prognosis and Analysis of Clinical Trials in traumatic brain injury models significantly increased their AUCs for predicting death (AUC range 0 center dot 90-0 center dot 94) and unfavourable outcome (AUC range 0 center dot 83-0 center dot 89). However, among participants with GCS score of 13-15 (n=1297), adding GFAP and UCH-L1 to the UPFRONT study model modestly increased the AUC for predicting incomplete recovery (AUC range 0 center dot 69-0 center dot 69, p=0 center dot 025). Interpretation In addition to their known diagnostic value, day-of-injury GFAP and UCH-L1 plasma concentrations have good to excellent prognostic value for predicting death and unfavourable outcome, but not for predicting incomplete recovery at 6 months. These biomarkers contribute the most prognostic information for participants presenting with a GCS score of 3-12.

Automated summary

The prognostic value of GFAP and UCH-L1 as predictors of functional outcome after traumatic brain injury is significant. GFAP and UCH-L1 have good to excellent prognostic value for predicting death and unfavorable outcome, but not for predicting incomplete recovery at 6 months. These biomarkers contribute the most prognostic information for participants with a GCS score of 3-12.